title: Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
abstract: OBJECTIVE
  To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB).
  
  
  METHODS
  A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed).
  
  
  RESULTS
  The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65).
  
  
  CONCLUSIONS
  Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.
authors.affiliation: Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Jinwoo
authors.initials: J
authors.lastname: Lee
authors.forename: Chang-Hoon
authors.initials: CH
authors.lastname: Lee
authors.forename: Deog Kyeom
authors.initials: DK
authors.lastname: Kim
authors.forename: Ho Il
authors.initials: HI
authors.lastname: Yoon
authors.forename: Jae Yeol
authors.initials: JY
authors.lastname: Kim
authors.forename: Sang-Min
authors.initials: SM
authors.lastname: Lee
authors.forename: Seok-Chul
authors.initials: SC
authors.lastname: Yang
authors.forename: Jae Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Chul-Gyu
authors.initials: CG
authors.lastname: Yoo
authors.forename: Choon-Taek
authors.initials: CT
authors.lastname: Lee
authors.forename: Hee Soon
authors.initials: HS
authors.lastname: Chung
authors.forename: Young Whan
authors.initials: YW
authors.lastname: Kim
authors.forename: Sung Koo
authors.initials: SK
authors.lastname: Han
authors.forename: Jae-Joon
authors.initials: JJ
authors.lastname: Yim
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D064704:Levofloxacin; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000472:pathogenicity; D016017:Odds Ratio; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D056910:Republic of Korea; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality
chemical_list: D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin